Aardvark Therapeutics annual free cash flow
2024
2025
Aardvark Therapeutics Free Cash Flow (FCF) History (AARD)
Aardvark Therapeutics reported −$54.3M in free cash flow for fiscal 2025, a decrease of $36.1M from the previous fiscal year.
View full Aardvark Therapeutics company overviewAardvark Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$54.3M | −$36.1M | — | — |
| 2024 | 2024-12-31 | −$18.2M | — | — | — |
Aardvark Therapeutics quarterly free cash flow
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −$16.8M | −$9.1M | — | — |
| Q3 2025 | 2025-09-30 | −$16.1M | −$12.2M | — | — |
| Q2 2025 | 2025-06-30 | −$9.9M | −$5.6M | — | — |
| Q1 2025 | 2025-03-31 | −$11.4M | −$9.2M | — | — |
| Q4 2024 | 2024-12-31 | −$7.7M | — | — | — |
| Q3 2024 | 2024-09-30 | −$4.0M | — | — | — |
| Q2 2024 | 2024-06-30 | −$4.3M | — | — | — |
| Q1 2024 | 2024-03-31 | −$2.2M | — | — | — |
Aardvark Therapeutics free cash flow growth trends
Aardvark Therapeutics's latest reported quarter, Q4 2025, generated −$16.8M in free cash flow, a decrease of $9.1M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Aardvark Therapeutics source filings ↗Community posts
FDA lifts Aardvark's ARD-101 hold as further trial planning continues
Aardvark Therapeutics ($AARD) said the FDA lifted the clinical hold on ARD-101, its investigational treatment for excessive hunger associated with Prader-Willi syndrome. The hold followed a voluntary dosing pause after reversible electrocar ...
